nodes	percent_of_prediction	percent_of_DWPC	metapath
Terazosin—Prazosin—CYP1A1—chronic obstructive pulmonary disease	0.006	1	CrCbGaD
Terazosin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00202	0.00214	CcSEcCtD
Terazosin—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.002	0.00213	CcSEcCtD
Terazosin—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00199	0.00212	CcSEcCtD
Terazosin—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00199	0.00212	CcSEcCtD
Terazosin—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.00198	0.00211	CcSEcCtD
Terazosin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00198	0.0021	CcSEcCtD
Terazosin—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00196	0.00209	CcSEcCtD
Terazosin—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.00195	0.00208	CcSEcCtD
Terazosin—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00195	0.00207	CcSEcCtD
Terazosin—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00195	0.00207	CcSEcCtD
Terazosin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00194	0.00206	CcSEcCtD
Terazosin—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00193	0.00206	CcSEcCtD
Terazosin—Cough—Formoterol—chronic obstructive pulmonary disease	0.00193	0.00205	CcSEcCtD
Terazosin—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00193	0.00205	CcSEcCtD
Terazosin—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00191	0.00203	CcSEcCtD
Terazosin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00191	0.00203	CcSEcCtD
Terazosin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.0019	0.00203	CcSEcCtD
Terazosin—Cough—Montelukast—chronic obstructive pulmonary disease	0.00189	0.00201	CcSEcCtD
Terazosin—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00188	0.002	CcSEcCtD
Terazosin—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00187	0.00199	CcSEcCtD
Terazosin—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00186	0.00197	CcSEcCtD
Terazosin—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00186	0.00197	CcSEcCtD
Terazosin—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00184	0.00196	CcSEcCtD
Terazosin—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00184	0.00196	CcSEcCtD
Terazosin—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00184	0.00196	CcSEcCtD
Terazosin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00184	0.00195	CcSEcCtD
Terazosin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00184	0.00195	CcSEcCtD
Terazosin—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00183	0.00195	CcSEcCtD
Terazosin—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00183	0.00195	CcSEcCtD
Terazosin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00182	0.00194	CcSEcCtD
Terazosin—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00182	0.00193	CcSEcCtD
Terazosin—Oedema—Formoterol—chronic obstructive pulmonary disease	0.0018	0.00192	CcSEcCtD
Terazosin—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.0018	0.00192	CcSEcCtD
Terazosin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.0018	0.00192	CcSEcCtD
Terazosin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.0018	0.00192	CcSEcCtD
Terazosin—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00177	0.00189	CcSEcCtD
Terazosin—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00177	0.00189	CcSEcCtD
Terazosin—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.00177	0.00189	CcSEcCtD
Terazosin—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00177	0.00188	CcSEcCtD
Terazosin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00176	0.00188	CcSEcCtD
Terazosin—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00176	0.00188	CcSEcCtD
Terazosin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00176	0.00188	CcSEcCtD
Terazosin—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00176	0.00187	CcSEcCtD
Terazosin—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00176	0.00187	CcSEcCtD
Terazosin—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00175	0.00186	CcSEcCtD
Terazosin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00174	0.00185	CcSEcCtD
Terazosin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00174	0.00185	CcSEcCtD
Terazosin—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00173	0.00184	CcSEcCtD
Terazosin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.0017	0.00181	CcSEcCtD
Terazosin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.0017	0.00181	CcSEcCtD
Terazosin—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.00168	0.00179	CcSEcCtD
Terazosin—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.00168	0.00179	CcSEcCtD
Terazosin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00167	0.00178	CcSEcCtD
Terazosin—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00167	0.00178	CcSEcCtD
Terazosin—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00166	0.00177	CcSEcCtD
Terazosin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00164	0.00175	CcSEcCtD
Terazosin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00164	0.00175	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00164	0.00175	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00164	0.00175	CcSEcCtD
Terazosin—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00163	0.00173	CcSEcCtD
Terazosin—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00163	0.00173	CcSEcCtD
Terazosin—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00162	0.00172	CcSEcCtD
Terazosin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00162	0.00172	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00161	0.00171	CcSEcCtD
Terazosin—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00161	0.00171	CcSEcCtD
Terazosin—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00161	0.00171	CcSEcCtD
Terazosin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.0016	0.0017	CcSEcCtD
Terazosin—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.0016	0.0017	CcSEcCtD
Terazosin—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.0016	0.0017	CcSEcCtD
Terazosin—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00159	0.00169	CcSEcCtD
Terazosin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00159	0.00169	CcSEcCtD
Terazosin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00159	0.00169	CcSEcCtD
Terazosin—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.00158	0.00169	CcSEcCtD
Terazosin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00158	0.00168	CcSEcCtD
Terazosin—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00157	0.00167	CcSEcCtD
Terazosin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00156	0.00166	CcSEcCtD
Terazosin—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.00156	0.00166	CcSEcCtD
Terazosin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.00155	0.00165	CcSEcCtD
Terazosin—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00155	0.00165	CcSEcCtD
Terazosin—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00155	0.00165	CcSEcCtD
Terazosin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00155	0.00165	CcSEcCtD
Terazosin—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00154	0.00164	CcSEcCtD
Terazosin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00154	0.00164	CcSEcCtD
Terazosin—Pain—Formoterol—chronic obstructive pulmonary disease	0.00154	0.00164	CcSEcCtD
Terazosin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00154	0.00164	CcSEcCtD
Terazosin—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00154	0.00164	CcSEcCtD
Terazosin—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00153	0.00162	CcSEcCtD
Terazosin—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00152	0.00162	CcSEcCtD
Terazosin—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00152	0.00161	CcSEcCtD
Terazosin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00151	0.00161	CcSEcCtD
Terazosin—Pain—Montelukast—chronic obstructive pulmonary disease	0.00151	0.0016	CcSEcCtD
Terazosin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.0015	0.0016	CcSEcCtD
Terazosin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.0015	0.00159	CcSEcCtD
Terazosin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00149	0.00159	CcSEcCtD
Terazosin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00149	0.00159	CcSEcCtD
Terazosin—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00149	0.00158	CcSEcCtD
Terazosin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00148	0.00158	CcSEcCtD
Terazosin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00148	0.00158	CcSEcCtD
Terazosin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00148	0.00158	CcSEcCtD
Terazosin—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00148	0.00157	CcSEcCtD
Terazosin—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.00148	0.00157	CcSEcCtD
Terazosin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00148	0.00157	CcSEcCtD
Terazosin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00147	0.00157	CcSEcCtD
Terazosin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00147	0.00157	CcSEcCtD
Terazosin—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00147	0.00156	CcSEcCtD
Terazosin—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00155	CcSEcCtD
Terazosin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00155	CcSEcCtD
Terazosin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00144	0.00153	CcSEcCtD
Terazosin—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.00144	0.00153	CcSEcCtD
Terazosin—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00142	0.00151	CcSEcCtD
Terazosin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00142	0.00151	CcSEcCtD
Terazosin—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00142	0.00151	CcSEcCtD
Terazosin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00142	0.00151	CcSEcCtD
Terazosin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00142	0.00151	CcSEcCtD
Terazosin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00141	0.0015	CcSEcCtD
Terazosin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00141	0.0015	CcSEcCtD
Terazosin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00141	0.0015	CcSEcCtD
Terazosin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.0014	0.00149	CcSEcCtD
Terazosin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.0014	0.00149	CcSEcCtD
Terazosin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00139	0.00148	CcSEcCtD
Terazosin—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00139	0.00148	CcSEcCtD
Terazosin—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.00139	0.00148	CcSEcCtD
Terazosin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00139	0.00148	CcSEcCtD
Terazosin—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00143	CcSEcCtD
Terazosin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00143	CcSEcCtD
Terazosin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00133	0.00141	CcSEcCtD
Terazosin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00133	0.00141	CcSEcCtD
Terazosin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00133	0.00141	CcSEcCtD
Terazosin—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00132	0.00141	CcSEcCtD
Terazosin—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.00131	0.0014	CcSEcCtD
Terazosin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.0013	0.00138	CcSEcCtD
Terazosin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00129	0.00137	CcSEcCtD
Terazosin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00129	0.00137	CcSEcCtD
Terazosin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00127	0.00136	CcSEcCtD
Terazosin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00127	0.00136	CcSEcCtD
Terazosin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00127	0.00135	CcSEcCtD
Terazosin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00133	CcSEcCtD
Terazosin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00125	0.00133	CcSEcCtD
Terazosin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00123	0.00131	CcSEcCtD
Terazosin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00123	0.00131	CcSEcCtD
Terazosin—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.00123	0.0013	CcSEcCtD
Terazosin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.00122	0.0013	CcSEcCtD
Terazosin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00121	0.00128	CcSEcCtD
Terazosin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.0012	0.00128	CcSEcCtD
Terazosin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00127	CcSEcCtD
Terazosin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00127	CcSEcCtD
Terazosin—KCNH6—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.00119	0.022	CbGpPWpGaD
Terazosin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00117	0.00124	CcSEcCtD
Terazosin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00116	0.00124	CcSEcCtD
Terazosin—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.00115	0.00122	CcSEcCtD
Terazosin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00115	0.00122	CcSEcCtD
Terazosin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00115	0.00122	CcSEcCtD
Terazosin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00121	CcSEcCtD
Terazosin—Rash—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00121	CcSEcCtD
Terazosin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00113	0.00121	CcSEcCtD
Terazosin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.00121	CcSEcCtD
Terazosin—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.00113	0.00121	CcSEcCtD
Terazosin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.0012	CcSEcCtD
Terazosin—Headache—Formoterol—chronic obstructive pulmonary disease	0.00113	0.0012	CcSEcCtD
Terazosin—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00113	0.0012	CcSEcCtD
Terazosin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.0012	CcSEcCtD
Terazosin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00112	0.00119	CcSEcCtD
Terazosin—Rash—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00118	CcSEcCtD
Terazosin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00118	CcSEcCtD
Terazosin—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.00111	0.00118	CcSEcCtD
Terazosin—Depression—Prednisone—chronic obstructive pulmonary disease	0.00111	0.00118	CcSEcCtD
Terazosin—Headache—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00118	CcSEcCtD
Terazosin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.00109	0.00116	CcSEcCtD
Terazosin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00115	CcSEcCtD
Terazosin—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00108	0.00115	CcSEcCtD
Terazosin—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.00107	0.00114	CcSEcCtD
Terazosin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00114	CcSEcCtD
Terazosin—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.00107	0.00114	CcSEcCtD
Terazosin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00114	CcSEcCtD
Terazosin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00107	0.00114	CcSEcCtD
Terazosin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00107	0.00114	CcSEcCtD
Terazosin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00113	CcSEcCtD
Terazosin—KCNH7—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.00106	0.0196	CbGpPWpGaD
Terazosin—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00105	0.00112	CcSEcCtD
Terazosin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00105	0.00111	CcSEcCtD
Terazosin—ADRA1D—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.00104	0.0192	CbGpPWpGaD
Terazosin—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.00104	0.0011	CcSEcCtD
Terazosin—KCNH7—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	0.00102	0.0189	CbGpPWpGaD
Terazosin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00107	CcSEcCtD
Terazosin—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.00101	0.00107	CcSEcCtD
Terazosin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000975	0.00104	CcSEcCtD
Terazosin—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000975	0.00104	CcSEcCtD
Terazosin—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00096	0.00102	CcSEcCtD
Terazosin—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000952	0.00101	CcSEcCtD
Terazosin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000943	0.001	CcSEcCtD
Terazosin—KCNH7—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000937	0.0174	CbGpPWpGaD
Terazosin—KCNH7—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000934	0.0173	CbGpPWpGaD
Terazosin—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000932	0.000992	CcSEcCtD
Terazosin—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000891	0.000948	CcSEcCtD
Terazosin—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000882	0.000938	CcSEcCtD
Terazosin—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000876	0.000932	CcSEcCtD
Terazosin—ADRA1D—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000871	0.0162	CbGpPWpGaD
Terazosin—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000868	0.000924	CcSEcCtD
Terazosin—ADRA1B—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.00086	0.016	CbGpPWpGaD
Terazosin—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000834	0.000887	CcSEcCtD
Terazosin—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000818	0.000871	CcSEcCtD
Terazosin—ADRA1D—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.00081	0.015	CbGpPWpGaD
Terazosin—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000806	0.000857	CcSEcCtD
Terazosin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000804	0.000855	CcSEcCtD
Terazosin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000794	0.000844	CcSEcCtD
Terazosin—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000783	0.000833	CcSEcCtD
Terazosin—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.00078	0.00083	CcSEcCtD
Terazosin—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000779	0.000828	CcSEcCtD
Terazosin—ADRA1A—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000764	0.0142	CbGpPWpGaD
Terazosin—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000763	0.000812	CcSEcCtD
Terazosin—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000752	0.0008	CcSEcCtD
Terazosin—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000739	0.000787	CcSEcCtD
Terazosin—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000739	0.000787	CcSEcCtD
Terazosin—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000737	0.000784	CcSEcCtD
Terazosin—ADRA1D—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	0.000734	0.0136	CbGpPWpGaD
Terazosin—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000731	0.000777	CcSEcCtD
Terazosin—ADRA1B—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000723	0.0134	CbGpPWpGaD
Terazosin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000719	0.000764	CcSEcCtD
Terazosin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000709	0.000754	CcSEcCtD
Terazosin—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000709	0.000754	CcSEcCtD
Terazosin—Shock—Prednisone—chronic obstructive pulmonary disease	0.000697	0.000742	CcSEcCtD
Terazosin—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000692	0.000736	CcSEcCtD
Terazosin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000685	0.000729	CcSEcCtD
Terazosin—ADRA1A—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	0.000683	0.0127	CbGpPWpGaD
Terazosin—ADRA1D—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000681	0.0126	CbGpPWpGaD
Terazosin—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000676	0.000719	CcSEcCtD
Terazosin—ADRA1B—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000672	0.0125	CbGpPWpGaD
Terazosin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000646	0.000687	CcSEcCtD
Terazosin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000645	0.000686	CcSEcCtD
Terazosin—ADRA1A—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000642	0.0119	CbGpPWpGaD
Terazosin—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000641	0.000682	CcSEcCtD
Terazosin—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000636	0.000677	CcSEcCtD
Terazosin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000624	0.000664	CcSEcCtD
Terazosin—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000616	0.000655	CcSEcCtD
Terazosin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000615	0.000654	CcSEcCtD
Terazosin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000614	0.000654	CcSEcCtD
Terazosin—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000611	0.00065	CcSEcCtD
Terazosin—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000611	0.00065	CcSEcCtD
Terazosin—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000606	0.000645	CcSEcCtD
Terazosin—ADRA1A—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000597	0.0111	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000587	0.0109	CbGpPWpGaD
Terazosin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000584	0.000621	CcSEcCtD
Terazosin—KCNH7—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.000582	0.0108	CbGpPWpGaD
Terazosin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00058	0.000617	CcSEcCtD
Terazosin—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000579	0.000616	CcSEcCtD
Terazosin—KCNH2—Hematopoietic Stem Cell Differentiation—IL1B—chronic obstructive pulmonary disease	0.000572	0.0106	CbGpPWpGaD
Terazosin—ADRA1B—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000565	0.0105	CbGpPWpGaD
Terazosin—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.00056	0.000596	CcSEcCtD
Terazosin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.00056	0.000596	CcSEcCtD
Terazosin—ADRA1B—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000558	0.0103	CbGpPWpGaD
Terazosin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000552	0.0102	CbGpPWpGaD
Terazosin—KCNH2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000549	0.0102	CbGpPWpGaD
Terazosin—KCNH7—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000542	0.0101	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000529	0.00982	CbGpPWpGaD
Terazosin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000522	0.000555	CcSEcCtD
Terazosin—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000509	0.000541	CcSEcCtD
Terazosin—ADRA1A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000502	0.00931	CbGpPWpGaD
Terazosin—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000501	0.000533	CcSEcCtD
Terazosin—ADRA1A—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000495	0.00919	CbGpPWpGaD
Terazosin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000485	0.000516	CcSEcCtD
Terazosin—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000469	0.000499	CcSEcCtD
Terazosin—ADRA1D—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	0.00046	0.00854	CbGpPWpGaD
Terazosin—KCNH7—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	0.000457	0.00848	CbGpPWpGaD
Terazosin—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000451	0.000479	CcSEcCtD
Terazosin—KCNH2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000447	0.0083	CbGpPWpGaD
Terazosin—Rash—Prednisone—chronic obstructive pulmonary disease	0.000447	0.000475	CcSEcCtD
Terazosin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000447	0.000475	CcSEcCtD
Terazosin—Headache—Prednisone—chronic obstructive pulmonary disease	0.000444	0.000472	CcSEcCtD
Terazosin—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000421	0.000448	CcSEcCtD
Terazosin—ADRA1A—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	0.000416	0.00772	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000367	0.00681	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	0.00036	0.00668	CbGpPWpGaD
Terazosin—ADRA1B—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000346	0.00643	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000345	0.00639	CbGpPWpGaD
Terazosin—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—chronic obstructive pulmonary disease	0.000335	0.00621	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000325	0.00603	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000319	0.00591	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000317	0.00589	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000314	0.00583	CbGpPWpGaD
Terazosin—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.00031	0.00576	CbGpPWpGaD
Terazosin—ADRA1A—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000308	0.00571	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000273	0.00507	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000267	0.00496	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000265	0.00491	CbGpPWpGaD
Terazosin—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000257	0.00478	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000252	0.00467	CbGpPWpGaD
Terazosin—ADRA1B—LPA receptor mediated events—CXCL8—chronic obstructive pulmonary disease	0.000244	0.00454	CbGpPWpGaD
Terazosin—KCNH7—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	0.000237	0.0044	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000235	0.00436	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000231	0.00429	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000231	0.00429	CbGpPWpGaD
Terazosin—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000229	0.00424	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000227	0.00421	CbGpPWpGaD
Terazosin—ADRA1B—LPA receptor mediated events—MMP9—chronic obstructive pulmonary disease	0.000221	0.0041	CbGpPWpGaD
Terazosin—KCNH7—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	0.000217	0.00403	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000216	0.004	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000208	0.00386	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000207	0.00384	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000206	0.00382	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000205	0.0038	CbGpPWpGaD
Terazosin—ADRA1D—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000202	0.00375	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000201	0.00374	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000201	0.00372	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.0002	0.00371	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000192	0.00357	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000192	0.00356	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000191	0.00354	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000181	0.00336	CbGpPWpGaD
Terazosin—ADRA1B—LPA receptor mediated events—EGFR—chronic obstructive pulmonary disease	0.000179	0.00332	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000173	0.0032	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000172	0.00318	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000171	0.00318	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.00017	0.00316	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00017	0.00316	CbGpPWpGaD
Terazosin—ADRA1B—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000168	0.00311	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000166	0.00308	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000163	0.00302	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000161	0.00298	CbGpPWpGaD
Terazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000156	0.0029	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000153	0.00284	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000153	0.00284	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000152	0.00283	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.00015	0.00278	CbGpPWpGaD
Terazosin—ADRA1A—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000149	0.00277	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000147	0.00273	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000146	0.0027	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000142	0.00264	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000141	0.00262	CbGpPWpGaD
Terazosin—ADRA1B—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.000141	0.00262	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.00014	0.00259	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000134	0.00248	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000133	0.00247	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000132	0.00246	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.00013	0.00242	CbGpPWpGaD
Terazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.00013	0.00241	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000127	0.00236	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000126	0.00234	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000126	0.00233	CbGpPWpGaD
Terazosin—ADRA1A—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.000125	0.00233	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000121	0.00224	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000118	0.00219	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000118	0.00218	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000117	0.00216	CbGpPWpGaD
Terazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000115	0.00214	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000113	0.0021	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000113	0.00209	CbGpPWpGaD
Terazosin—KCNH2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	0.000113	0.00209	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000111	0.00206	CbGpPWpGaD
Terazosin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000111	0.00205	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.00011	0.00204	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000108	0.00201	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000107	0.00199	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000107	0.00198	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000103	0.00191	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000102	0.00189	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	9.87e-05	0.00183	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	9.76e-05	0.00181	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	9.75e-05	0.00181	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	9.67e-05	0.0018	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	9.62e-05	0.00178	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	9.57e-05	0.00178	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	8.86e-05	0.00164	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	8.82e-05	0.00164	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	8.79e-05	0.00163	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	8.66e-05	0.00161	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	8.59e-05	0.00159	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	8.56e-05	0.00159	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	8.46e-05	0.00157	CbGpPWpGaD
Terazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	8.27e-05	0.00153	CbGpPWpGaD
Terazosin—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	8.21e-05	0.00152	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	8.17e-05	0.00152	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.87e-05	0.00146	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.82e-05	0.00145	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	7.61e-05	0.00141	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	7.52e-05	0.00139	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	7.37e-05	0.00137	CbGpPWpGaD
Terazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	6.87e-05	0.00127	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	6.78e-05	0.00126	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	6.69e-05	0.00124	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	6.59e-05	0.00122	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	6.49e-05	0.0012	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.3e-05	0.00117	CbGpPWpGaD
Terazosin—ADRA1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	6.3e-05	0.00117	CbGpPWpGaD
Terazosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	6.28e-05	0.00116	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	6.12e-05	0.00114	CbGpPWpGaD
Terazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	6.1e-05	0.00113	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	6.02e-05	0.00112	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	5.98e-05	0.00111	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.85e-05	0.00108	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.77e-05	0.00107	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	5.76e-05	0.00107	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	5.69e-05	0.00106	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	5.56e-05	0.00103	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	5.47e-05	0.00101	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	5.43e-05	0.00101	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.29e-05	0.000981	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	5.23e-05	0.000971	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	5.23e-05	0.000971	CbGpPWpGaD
Terazosin—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	5.23e-05	0.00097	CbGpPWpGaD
Terazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	5.21e-05	0.000966	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.96e-05	0.000921	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.93e-05	0.000916	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.86e-05	0.000901	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.78e-05	0.000887	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	4.72e-05	0.000877	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.65e-05	0.000862	CbGpPWpGaD
Terazosin—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.64e-05	0.000862	CbGpPWpGaD
Terazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	4.63e-05	0.000858	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.61e-05	0.000855	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.53e-05	0.000841	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	4.41e-05	0.000818	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	4.34e-05	0.000806	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	4.34e-05	0.000805	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.28e-05	0.000795	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	4.25e-05	0.000789	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.25e-05	0.000788	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	4.05e-05	0.000751	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.95e-05	0.000734	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.86e-05	0.000716	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.83e-05	0.00071	CbGpPWpGaD
Terazosin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.57e-05	0.000662	CbGpPWpGaD
Terazosin—ADRA1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.56e-05	0.000661	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.56e-05	0.00066	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.53e-05	0.000656	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.4e-05	0.00063	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.28e-05	0.000609	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.23e-05	0.0006	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.21e-05	0.000596	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.16e-05	0.000586	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.11e-05	0.000576	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.09e-05	0.000574	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	3.07e-05	0.00057	CbGpPWpGaD
Terazosin—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.95e-05	0.000548	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.93e-05	0.000544	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.92e-05	0.000541	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.87e-05	0.000533	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.8e-05	0.00052	CbGpPWpGaD
Terazosin—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.72e-05	0.000505	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.68e-05	0.000498	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.67e-05	0.000495	CbGpPWpGaD
Terazosin—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.62e-05	0.000487	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.61e-05	0.000483	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.58e-05	0.000479	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.57e-05	0.000476	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.39e-05	0.000443	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.38e-05	0.000442	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.37e-05	0.000439	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.36e-05	0.000438	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.28e-05	0.000423	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.26e-05	0.000418	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.15e-05	0.0004	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.15e-05	0.000399	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.12e-05	0.000394	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.12e-05	0.000393	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.98e-05	0.000367	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.96e-05	0.000364	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.91e-05	0.000354	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.88e-05	0.000348	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.87e-05	0.000347	CbGpPWpGaD
Terazosin—ADRA1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.82e-05	0.000337	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.79e-05	0.000332	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.74e-05	0.000323	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.73e-05	0.000321	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.66e-05	0.000308	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.59e-05	0.000295	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.59e-05	0.000294	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.55e-05	0.000288	CbGpPWpGaD
Terazosin—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.51e-05	0.00028	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.43e-05	0.000266	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.42e-05	0.000264	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.41e-05	0.000261	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.4e-05	0.000259	CbGpPWpGaD
Terazosin—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.34e-05	0.000248	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.29e-05	0.000239	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.28e-05	0.000237	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.27e-05	0.000236	CbGpPWpGaD
Terazosin—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.22e-05	0.000226	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.18e-05	0.000219	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.17e-05	0.000217	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.16e-05	0.000215	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.14e-05	0.000212	CbGpPWpGaD
Terazosin—ADRA1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.07e-05	0.000199	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.05e-05	0.000195	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.03e-05	0.000191	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	9.73e-06	0.00018	CbGpPWpGaD
Terazosin—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	8.9e-06	0.000165	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.64e-06	0.00016	CbGpPWpGaD
Terazosin—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.91e-06	0.000147	CbGpPWpGaD
